The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws, alleging the biopharmaceutical company and certain executives made materially false and/or misleading statements regarding its business and operations. The firm is seeking investors who suffered losses and potential witnesses to contact them.

Robbins Geller Rudman & Dowd LLP has launched an investigation into Travere Therapeutics, Inc. for potential violations of U.S. federal securities laws. The investigation examines whether Travere and its executives made materially false or misleading statements regarding the company's business and operations. The law firm is seeking investors who suffered losses and potential witnesses to contact them.

Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

The American Kidney Fund hosted its third annual Patient Access Initiative Summit focusing on innovative kidney care technologies, AI applications, and addressing barriers to kidney disease prevention and treatment.

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition. If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS.

Travere Therapeutics announced that it granted inducement equity grants covering 115,100 shares of its common stock to ten new employees, consisting of stock options and restricted stock units. These grants were made as inducements to the new employees to join the company.

Travere Therapeutics, a biopharmaceutical company focused on rare diseases, announced that its president and CEO will present at the upcoming J.P. Morgan Healthcare Conference.

Travere Therapeutics announced that it granted inducement equity grants to six new employees, consisting of restricted stock units covering 24,400 shares of its common stock. The RSUs vest over four years, subject to the new employees' continued service.

Travere Therapeutics announced the pricing of a public offering of 7,812,500 shares of its common stock at $16.00 per share, raising $125 million in gross proceeds. The offering is expected to close on November 12, 2024.